Jia (Jenny) Liu: The First Early Phase Trials I Have Had the Privilege of Conducting as PI
Jia (Jenny) Liu, Translational Lead, Early Phase Drug Development at The Kinghorn Cancer Centre, shared on LinkedIn:
“DEP-SN38 early phase trial results just published in American Society of Clinical Oncology (ASCO) JCO
On the 4 year anniversary of my role as drug development medical oncologist at The Kinghorn Cancer Centre, I am delighted to share the published results from one of the first early phase trials I have had the privilege of conducting as PI.
As TOPi payload ADC drug development, these findings suggest that alternative technologies can also improve the cytotoxic delivery of payloads like SN38, using poly-lysine dendrimer nanotechnology.
This first-in-human study conducted across demonstrates:
- Promising activity in heavily pretreated patients (n=114) ovarian, colorectal, pancreatic & breast cancers; median 4 prior lines therapy
- At RP2D of 12.5mg/m2, lower rates of severe GI toxicity and no cholinergic toxicity compared to irinotecan
- Signals of prolonged benefit even in heavily pre-treated patients, with many returning to work and everyday activities while on trial.
Dendrimer technologies have potential broader applicability in oncology drug development to deliver payloads with greater efficacy due to EPR (enhanced permeability and retention effect) in the tumor micro environment.
Congratulations to all coauthors, especially my friend and senior coauthor Natalie Cook The Christie NHS Foundation Trust Experimental Cancer Medicine Centres Network (ECMC) as well as collaborators across sites, and Starpharma for developing this innovative platform.
Immense gratitude to all participating patients/families and referring oncologists, and especially our wonderful site teams Robert Kent, Aaron O’Grady including the many, many coordinators who have worked on the study over several years Jacob Yousif, Ivan Ly, Oksana Zdanska, Arvin Caraos…
Title: Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors
Authors: Jia (Jenny) Liu, Anna R. Minchom, Alastair Greystoke, Thomas R.J. Evans, Debashis Sarker, Anthony M. Joshua, Cienne Morton, Wing Yau, Burak Y. Aktas, Rasha Cosman, Jordan E. Cohen, Stephanie R. Edmondson, Jeremy R.A. Paull, Bernadette M. Jean-Francois, Nicola J. Main, Julia Angeles, Alex Castellarnau, Natalie Cook.
More posts featuring Jia Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023